PM PST Webcast: A replay of the event will be available for 90 days and can be accessed by visiting the “ Investor Calendar ...
A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous ...
Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...
Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.
The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...
Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033" has been added ...
Vera Therapeutics received priority review from the FDA for its biologics license application for atacicept to treat adults ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
Investing.com -- Vera Therapeutics Inc (NASDAQ:VERA) stock rose 4.4% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License ...
EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative biotechnology company focused on developing ...
Injectable filler could help breast cancer patients avoid complex reconstruction procedures, though human trials are still needed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback